Table 3.
Demographic data for study subjects
| Sample | Age (Range in yrs.) | Diagnosis | Duration (years) | Current Meds | Previous Treatments | Past Med History |
|---|---|---|---|---|---|---|
| VL1009B | 60–69 | Vitiligo | 10 | None | topical and oral steroid | HTN |
| VL1010B | 50–59 | Vitiligo | 2 | None | steroid (1.5 yrs ago) | hypothyroid |
| VL1016Ba | 70–79 | Vitiligo | 50 | ASA, atenolol, lipitor, detrol LA | Methoxsalen (45–50 yrs. ago), none currently | None |
| VL1017Ba | 30–39 | Vitiligo | 10 | PABA, vitamin B12, trazodone and other antianxiety med | light treatment (6 yrs. ago), Vit B12 injection | None |
| VL1018Ba | 30–39 | Vitiligo | 12 | None | None | None |
| VL1019Ba | 30–39 | Vitiligo | 26 | None | None | Factor V disorder |
| VL1020B | 60–69 | Vitiligo | 30 | None | None | None |
| VL1021B | 60–69 | Vitiligo | >20 | sunblock | benoquin (depigmentation agent) | rosacea (10yrs ago), osteoarthritis, SCC (10yrs ago) |
| NL1001B | 50–59 | No disease | none | none | none | none |
| NL1004B | 30–39 | No disease | none | none | none | none |
| NL1013B | 30–39 | No disease | none | none | none | none |
| NL1014B | 40–49 | No disease | none | none | none | none |
| NL1020B | 50–59 | No disease | none | none | none | none |
| NL1032B | 40–49 | No disease | none | none | none | none |
Abbreviations: VL vitiligo, NL normal, B blood, PABA para amino benzoic acid, HTN hypertension, SCC squamous cell carcinoma, ASA amino salicylic acid, LA long acting. Patients were under no systemic or topical medications for 2 months prior to sampling. aStarred samples are shared between our previous skin and the present blood analyses. Gender and ethnicity details are withheld to protect patient privacy. While the healthy controls were 100% females, the female to male ratio in vitiligo patients is 6.2: 3.8. Ethnicity distribution among healthy controls is 67% African American, 17% Caucasian and 17% Asian and among VL patients 50% Caucasians, 25% Hispanics, 12.5% Asian and 12.5% African